Jci_page_head_homepage_01 Jci_page_head_homepage_02
Karl-Dimiter Bissig, Stefan F. Wieland, Phu Tran, Masanori Isogawa, Tam T. Le, Francis V. Chisari, Inder M. Verma
Published in Volume 120, Issue 3
J Clin Invest. 2010; 120(3):924–930 doi:10.1172/JCI40094
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
HCV infection of mice with high human chimerism.

HCV RNA in mouse serum after inoculation with HCV genotype 2a (A) or clinical isolate of HCV genotype 1a or chimeric HCV genotypes (1a/2a and 1b/2a) (B). (C) HCV RNA intermediates detected in chimeric livers and human albumin levels in the murine serum of HCV-infected mice. HCV RNA was normalized to human GAPDH levels and expressed as GE per μg total RNA. (D) Antiviral treatment with peg-IFN alone, peg-IFN and ribavirin, and peg-IFN and Debio 025 for 2 weeks. Results are shown as normalized mean ± SD. (EG) Fluorescent costaining of an HCV-infected chimeric liver for FAH (green) and HCV NS5a (red); nuclear counterstaining with DAPI (blue). (E) FAH and nuclear staining. (F) NS5a and nuclear staining. (G) Merge of E and F showing colocalization of HCV and human hepatocytes in yellow. (H) Control mouse liver repopulated with human hepatocytes but not inoculated with HCV. Costaining for FAH (green) and HCV NS5a (red); nuclear counterstaining with DAPI (blue). Scale bars: 50 μm.